Loading cancer entity…
Loading cancer entity…
Clinical trials
3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07005297 | Clinical Genetics Branch Eligibility Screening Survey | not yet recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT02897479 |
| A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer |
| unknown |
| Phase 2 |
| 76 |
| Hutchison Medipharma LimitedINDUSTRY |
| 1 |
| Nov 30, 2021 |
| clinicaltrials |
Data updated 22 hours agoSource updated Sep 28, 2026source: clinicaltrials